Tetra Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for patients with cognitive impairment and memory loss, today announced it has entered into an expanded strategic alliance with Shionogi. The two companies will work together to develop and commercialize BPN14770 for the treatment of Alzheimer’s disease, Fragile X syndrome and other indications marked by cognitive and memory deficits. ...
Tetra Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for patients with cognitive impairment and memory loss, today announced it has entered into an expanded strategic alliance with Shionogi. The two companies will work together to develop and commercialize BPN14770 for the treatment of Alzheimer’s disease, Fragile X syndrome and other indications marked by cognitive and memory deficits. Under the terms of the expanded alliance, Shionogi has increased its equity investment in the company to
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.